Other News

Shimadzu Medical Systems announces Release of New Angiography System at the SIR 2022

TORRANCE, Calif., June 12, 2022 /PRNewswire/ — Shimadzu Corporation will commence worldwide sales of its flagship newest version of its Trinias™ angiography system. Shimadzu Medical Systems USA will introduce our innovative new technology solutions in angiography at the SIR 2022 conference, starting on Sunday, June 12, 2022. The new Trinias system uses AI deep learning […]

Philips announces positive three-year clinical research results from its Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial

For below-the-knee arterial dissection repair following balloon angioplasty, innovative medical technology shows sustained treatment effect and positive impact on quality of life for patients with critical limb ischemia (CLI) First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage (93.9%) and freedom from clinically-driven […]

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions

LEXINGTON, Mass., June 13, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from a preclinical […]

Cytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions

Echocardiographic Data Show Treatment with Aficamten for 10 Weeks Results In Improved Cardiac Structure, Myocardial Relaxation and Mitral Valve Mechanics SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from a new analysis of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) […]

Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. “Bo” Cumbo, to its Board of Directors

CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Alexander G. “Bo” Cumbo, chief executive officer and president of AavantiBio, Inc., has joined the company’s board of directors. “Bo […]

Valbiotis announces the major success of the Phase II HEART clinical study: the patented plant-based active substance TOTUM•070 proves its efficacy against hypercholesterolemia, a cardiovascular risk factor

This randomized, placebo-controlled Phase II clinical study with TOTUM•070 achieved its objective of reducing LDL cholesterol (primary endpoint) and confirmed the very good tolerance of this active substance. As early as 3 months of supplementation, the results showed a significant reduction in blood levels of LDL cholesterol (-13%) and triglycerides […]

Almost 1 In Every 4 Adult Male Deaths in the United States is Caused by Heart Disease and African American men account for 100,000 more Cardiovascular Disease Deaths than Caucasian Men

TAMPA, Fla., June 9, 2022 /PRNewswire/ — Smart Meter, continues to lead the way in the remote patient monitoring (RPM) sector because of its superior cellular-enabled devices and robust data that facilitate better care management. During Men’s Health Month, Smart Meter wants to remind patients and providers that high blood pressure and obesity, […]

Amarin Receives Positive Recommendation from United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl)

UK’s NICE issued its draft Final Appraisal Document (FAD) recommending the use of VAZKEPA® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high CV risk who have elevated triglycerides (≥150 mg/dL [≥ 1.7 mmol/L]) and established cardiovascular disease (eCVD) 1,2 Positive […]

Acarix signs additional commercial agreement in US and receives order for CADScor®System in Louisiana.

Acarix continues the US expansion with another commercial partnership now covering Louisiana and parts of Mississippi. This partnership with Bio-Rhythms Inc provides access to cardiology clinics, emergency departments and primary care clinics in geographic areas with high medical need for rapid and cost-effective rule-out of coronary artery disease. Louisiana is among the top 5 US states based on […]